AN2 Therapeutics, Inc.(ANTX)

Biotechnology · Menlo Park, CA

$5.07-0.54 (-9.63%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T22:20:44.833Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:20:44.833Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 5.07
Unrounded diluted TTM EPS · period ending 2026-06-30: -1.07

FMP input reference: 66e3eaee1cdd755dffe0dd2f4d89b3fc137545160e5faabf240127d9674bae42

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

ANTX PE Ratio Metrics

PE RATIO

N/A

ANTX Competitors' PE Ratio

ANTX

AN2 Therapeutics, Inc.

Current

Market Cap

$182.60M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNTN

Canton Strategic Holdings Inc

vs ANTX

Market Cap

$180.47M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CMPX

Compass Therapeutics, Inc.

vs ANTX

Market Cap

$179.75M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORMP

Oramed Pharmaceuticals Inc.

vs ANTX

Market Cap

$179.26M

PE Ratio

1.07

TTM Avg

2.35

3Y Avg

8.36

5Y Avg

8.36

ELDN

Eledon Pharmaceuticals, Inc.

vs ANTX

Market Cap

$189.11M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ZNTL

Zentalis Pharmaceuticals, Inc.

vs ANTX

Market Cap

$190.07M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

YARW

Yarrow Bioscience Inc

vs ANTX

Market Cap

$174.27M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRQR

ProQR Therapeutics N.V.

vs ANTX

Market Cap

$173.76M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RXST

RxSight, Inc.

vs ANTX

Market Cap

$192.49M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORGO

Organogenesis Holdings Inc.

vs ANTX

Market Cap

$172.42M

PE Ratio

N/A

TTM Avg

22.05

3Y Avg

43.38

5Y Avg

28.58

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
AN2 Therapeutics, Inc. (ANTX)	$182.60M	N/A	N/A	N/A	N/A
Canton Strategic Holdings Inc (CNTN)vs ›	$180.47M	N/A	N/A	N/A	N/A
Compass Therapeutics, Inc. (CMPX)vs ›	$179.75M	N/A	N/A	N/A	N/A
Oramed Pharmaceuticals Inc. (ORMP)vs ›	$179.26M	1.07	2.35	8.36	8.36
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$189.11M	N/A	N/A	N/A	N/A
Zentalis Pharmaceuticals, Inc. (ZNTL)vs ›	$190.07M	N/A	N/A	N/A	N/A
Yarrow Bioscience Inc (YARW)vs ›	$174.27M	N/A	N/A	N/A	N/A
ProQR Therapeutics N.V. (PRQR)vs ›	$173.76M	N/A	N/A	N/A	N/A
RxSight, Inc. (RXST)vs ›	$192.49M	N/A	N/A	N/A	N/A
Organogenesis Holdings Inc. (ORGO)vs ›	$172.42M	N/A	22.05	43.38	28.58

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$5.07

Forward EPS (Est.)

$-0.89

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

ANTX PE Ratio Metrics

ANTX Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics